Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03540160 · ClinicalTrials.gov registry record · Phase 3
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
A Phase 3 study, sponsored by Vyne Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
NCT03540160 is a Phase 3 study that was terminated before completion, run by Vyne Therapeutics. The registered enrollment target is 558 participants.
The verdict
NCT03540160, a Phase 3 study, was terminated before completion, sponsored by Vyne Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
Study Summary
Study of the long term safety of serlopitant for the treatment of pruritus in adults.
Interventions
- DRUG 5 mg Serlopitant Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2020-06-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03540160
The ClinicalTrials.gov registry entry for NCT03540160 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 5 mg Serlopitant Tablets is the first listed.
NCT03540160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03540160 about?
NCT03540160 is a clinical study titled "Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)". Study of the long term safety of serlopitant for the treatment of pruritus in adults.
What is the current status of trial NCT03540160?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2018-03-15. Estimated completion is 2020-06-17.
What interventions are being tested in trial NCT03540160?
The interventions under investigation include: 5 mg Serlopitant Tablets (DRUG).
Who is sponsoring clinical trial NCT03540160?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.